Market Research Logo

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016’, provides an overview of the Daiichi Sankyo Company, Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Daiichi Sankyo Company, Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:*:Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Daiichi Sankyo Company, Limited
  • The report provides overview of Daiichi Sankyo Company, Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Daiichi Sankyo Company, Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Daiichi Sankyo Company, Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Daiichi Sankyo Company, Limited’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Daiichi Sankyo Company, Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Daiichi Sankyo Company, Limited’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Daiichi Sankyo Company, Limited Snapshot
Daiichi Sankyo Company, Limited Overview
Key Facts
Daiichi Sankyo Company, Limited - Research and Development Overview
Key Therapeutic Areas
Daiichi Sankyo Company, Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Daiichi Sankyo Company, Limited - Pipeline Products Glance
Daiichi Sankyo Company, Limited - Late Stage Pipeline Products
Daiichi Sankyo Company, Limited - Clinical Stage Pipeline Products
Daiichi Sankyo Company, Limited - Early Stage Pipeline Products
Daiichi Sankyo Company, Limited - Unknown Stage Pipeline Products
Daiichi Sankyo Company, Limited - Drug Profiles
A-503451A - Drug Profile
CS-1050 - Drug Profile
DC-159a - Drug Profile
denosumab - Drug Profile
DF-461 - Drug Profile
Drug to Inhibit IDH1 for Acute Myelocytic Leukemia and Glioma - Drug Profile
Drugs for Oncology, Cardiovascular and Metabolic Diseases - Drug Profile
DS-1040 - Drug Profile
DS-1093 - Drug Profile
DS-1123 - Drug Profile
DS-1501 - Drug Profile
DS-1558 - Drug Profile
DS-1971 - Drug Profile
DS-2330 - Drug Profile
DS-2969 - Drug Profile
DS-3032 - Drug Profile
DS-3201 - Drug Profile
DS-5141 - Drug Profile
DS-5272 - Drug Profile
DS-5573a - Drug Profile
DS-6051 - Drug Profile
DS-7080 - Drug Profile
DS-8108b - Drug Profile
DS-8201 - Drug Profile
DS-8273 - Drug Profile
DS-8500 - Drug Profile
DS-8895 - Drug Profile
DS-9001 - Drug Profile
DS-9231 - Drug Profile
edoxaban tosylate - Drug Profile
efatutazone - Drug Profile
esaxerenone - Drug Profile
etanercept biosimilar - Drug Profile
etirinotecan pegol - Drug Profile
hydromorphone hydrochloride - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
laninamivir - Drug Profile
mirogabalin besylate - Drug Profile
Monoclonal Antibodies for Undisclosed Indication - Drug Profile
Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer - Drug Profile
nimotuzumab - Drug Profile
patritumab - Drug Profile
Pedopeptins to Inhibit LPS for Bacterial Infection - Drug Profile
PLX-51107 - Drug Profile
PLX-73086 - Drug Profile
PLX-7486 - Drug Profile
PLX-8394 - Drug Profile
PLX-9486 - Drug Profile
prasugrel hydrochloride - Drug Profile
Protein for Undisclosed Indication - Drug Profile
quizartinib dihydrochloride - Drug Profile
R-xxx - Drug Profile
Small Molecule for Cardiovascular-Metabolic Diseases - Drug Profile
Small Molecule for Respiratory Tract Infections - Drug Profile
Small Molecule for Tuberculosis - Drug Profile
Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile
Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders - Drug Profile
Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile
Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile
Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis - Drug Profile
Small Molecule to Inhibit PDE4 for COPD - Drug Profile
Small Molecule to Inhibit PDE4B for Lung Inflammation - Drug Profile
Small Molecule to Inhibit Renin for Hypertension - Drug Profile
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
Small Molecules for Malaria - Drug Profile
Small Molecules for Multiple Neurodegenerative Diseases - Drug Profile
Small Molecules for Osteopenia and Osteoporosis - Drug Profile
Small Molecules to Agonize BRS-3 for Obesity - Drug Profile
Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile
Small Molecules to Inhibit FATP1 for Undisclosed Indication - Drug Profile
Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile
Small Molecules to Inhibit Nav1.7 for Pain - Drug Profile
Small Molecules to Inhibit p53-MDM2 Interaction for Cancer - Drug Profile
Sphaerimicin A - Drug Profile
SQ-641 - Drug Profile
Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile
tivantinib - Drug Profile
U-31402 - Drug Profile
U-3771 - Drug Profile
U-3808 - Drug Profile
U3-1784 - Drug Profile
VN-0102 - Drug Profile
VN-0103 - Drug Profile
VN-0104 - Drug Profile
VN-0105 - Drug Profile
VN-100 - Drug Profile
Daiichi Sankyo Company, Limited - Pipeline Analysis
Daiichi Sankyo Company, Limited - Pipeline Products by Target
Daiichi Sankyo Company, Limited - Pipeline Products by Route of Administration
Daiichi Sankyo Company, Limited - Pipeline Products by Molecule Type
Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action
Daiichi Sankyo Company, Limited - Dormant Projects
Daiichi Sankyo Company, Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Daiichi Sankyo Company, Limited - Company Statement
Daiichi Sankyo Company, Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Daiichi Sankyo Company, Limited, Key Facts
Daiichi Sankyo Company, Limited - Pipeline by Indication, 2016
Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016
Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016
Daiichi Sankyo Company, Limited - Combination Treatment Modalities in Pipeline, 2016
Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016
Daiichi Sankyo Company, Limited - Partnered Products/ Combination Treatment Modalities, 2016
Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016
Daiichi Sankyo Company, Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
Daiichi Sankyo Company, Limited - Pre-Registration, 2016
Daiichi Sankyo Company, Limited - Phase III, 2016
Daiichi Sankyo Company, Limited - Phase II, 2016
Daiichi Sankyo Company, Limited - Phase I, 2016
Daiichi Sankyo Company, Limited - Preclinical, 2016
Daiichi Sankyo Company, Limited - Discovery, 2016
Daiichi Sankyo Company, Limited - Unknown, 2016
Daiichi Sankyo Company, Limited - Pipeline by Target, 2016
Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016
Daiichi Sankyo Company, Limited - Pipeline by Molecule Type, 2016
Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action, 2016
Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2016
Daiichi Sankyo Company, Limited - Discontinued Pipeline Products, 2016
Daiichi Sankyo Company, Limited, Subsidiaries
List of Figures
Daiichi Sankyo Company, Limited - Pipeline by Top 10 Indication, 2016
Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016
Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016
Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016
Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016
Daiichi Sankyo Company, Limited - Pipeline by Top 10 Target, 2016
Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016
Daiichi Sankyo Company, Limited - Pipeline by Top 10 Molecule Type, 2016
Daiichi Sankyo Company, Limited - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report